Entelexo Analysis: $125K Raised
What is Entelexo?
Entelexo develops exosome-based therapeutics targeting autoimmune diseases, utilizing engineered exosomes for communication with specific cell types.
Employees
3
Founded
2020
Revenue
$5M
Investors
- Founders, Inc.
- Y Combinator
Product Features & Capabilities
- engineered exosomes for autoimmune diseases, therapeutic exosome-based products, rapid prototyping of therapeutics, indication-specific exosome treatments, communication with multiple cell types
How much Entelexo raised
Seed - $125,000
March 24, 2021Lead Investor: Y Combinator
Who are the founders of Entelexo
Competitors Overview
Entelexo operates in the exosome-based therapeutics market, focusing on treatments for autoimmune diseases. Its main competitors include:
- Glycominds: This company specializes in glycoengineering and exosome-based therapies, particularly for autoimmune and inflammatory diseases. Glycominds le
Market Focus
Entelexo primarily focuses on the biotechnology industry, specifically in the development of exosome-based therapeutics for treating autoimmune diseases.
See something that needs updating? Suggest edits to this profile.